 |
|
Plants can be used to study how and why people respond differently to drugs
September 27, 2007RIVERSIDE, Calif. - While prescription medications work successfully to cure an ailment in some people, in others the same dose of the same drug can cause an adverse reaction or no response at all.
According to a research team led by Sean Cutler, an assistant professor of plant cell biology at UC Riverside, such variation in drug responses can be analyzed by studying much simpler organisms - like plants.
"The genetics behind variable drug responses is not peculiar to humans but exists also in other branches on the tree of life," Cutler said. "We can harness simple organisms to understand more about the genetics and biochemistry of variable drug responses, which could help uncover new factors that contribute to variable drug responses in humans."
Study results appear in the Sept. 23 online publication of Nature Chemical Biology.
Focusing on Arabidopsis thaliana, a weedy plant in the mustard family, Cutler's lab discovered a key protein in the plant that creates drug resistance. Called UGT (UDP-glycosyltransferase), the protein is a member of a family of proteins that also affect drug sensitivity in humans.
"Similar biochemical processes are affecting drug sensitivity in both plants and animals," said Cutler, who joined UCR's Department of Botany and Plant Sciences and the Center for Plant Cell Biology in January 2007. "These similarities suggest that plants can be useful for studying problems of human interest like drug responses."
In their research, Cutler and his research team first screened and tested thousands of drug-like compounds in the lab as they searched for new inhibitors of plant growth. In the process, they discovered a new molecule, called hypostatin, which acts like a drug in inhibiting plant growth in some Arabidopsis plants.
At the same time, the researchers grew Arabidopsis plants in a solution containing hypostatin, which allowed the plant cells to take up hypostatin.
Cutler and his team found that the plants' UGT activates hypostatin by adding a sugar molecule to it. They also found that in plants that had a genetically defective UGT, hypostatin did not work properly because no sugar molecules - necessary for activating hypostatin - were added to it; in such plants, therefore, growth was not affected.
"This mechanism is very similar to that seen in humans, where altered drug sensitivity can occur because of defective or atypical sugar-tagging proteins," Cutler said.
His lab made the discovery as part of its ongoing research aimed at identifying and characterizing new bioactive compounds in plants. Next in their research, Cutler and his colleagues plan to expand their search for other sugar-activated molecules, like hypostatin.
University of California - Riverside
Study results appear in the Sept. 23 online publication of Nature Chemical Biology.
Focusing on Arabidopsis thaliana, a weedy plant in the mustard family, Cutler's lab discovered a key protein in the plant that creates drug resistance. Called UGT (UDP-glycosyltransferase), the protein is a member of a family of proteins that also affect drug sensitivity in humans.
"Similar biochemical processes are affecting drug sensitivity in both plants and animals," said Cutler, who joined UCR's Department of Botany and Plant Sciences and the Center for Plant Cell Biology in January 2007. "These similarities suggest that plants can be useful for studying problems of human interest like drug responses."
In their research, Cutler and his research team first screened and tested thousands of drug-like compounds in the lab as they searched for new inhibitors of plant growth. In the process, they discovered a new molecule, called hypostatin, which acts like a drug in inhibiting plant growth in some Arabidopsis plants.
At the same time, the researchers grew Arabidopsis plants in a solution containing hypostatin, which allowed the plant cells to take up hypostatin.
Cutler and his team found that the plants' UGT activates hypostatin by adding a sugar molecule to it. They also found that in plants that had a genetically defective UGT, hypostatin did not work properly because no sugar molecules - necessary for activating hypostatin - were added to it; in such plants, therefore, growth was not affected.
"This mechanism is very similar to that seen in humans, where altered drug sensitivity can occur because of defective or atypical sugar-tagging proteins," Cutler said.
His lab made the discovery as part of its ongoing research aimed at identifying and characterizing new bioactive compounds in plants. Next in their research, Cutler and his colleagues plan to expand their search for other sugar-activated molecules, like hypostatin.
University of California - Riverside
Drug Response Current Events and Drug Response News RSSNew cancer drug test promises safer and more effective clinical trials
A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development.
Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia
Scientists at St. Jude Children's Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.
A crystal ball for brain cancer?
UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment.
New 3-D structural model of critical H1N1 protein developed
In just two weeks from the time the first patient virus samples were made available, Singapore scientists report an evolutionary analysis of a critical protein produced by the 2009 H1N1 influenza A virus strain.
Tumor growth and chemo response may be predicted by mathematical model
The aggressiveness of tumors and their susceptibility to chemotherapy may become easier to predict based on a mathematical model developed at The University of Texas Health Science Center at Houston.
Are we cherry picking participants for studies of antidepressants?
Findings from clinical studies used to gain Food and Drug Administration approval of common antidepressants are not applicable to most patients with depression, according to a report led by the University of Pittsburgh Graduate School of Public Health.
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment. Just as important, knowing which of a patient's cancer-causing genetic lesions are contributing to drug resistance might help doctors redesign therapy for maximum benefit.
Antidepressants in suicide prevention
Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement.
Environmental enrichment can reduce cocaine use, researchers find
Simple environmental enrichment and increased social stress can both affect the level of individual drug use, according to new monkey research at Wake Forest University School of Medicine.
Johns Hopkins to participate in 1000 Genomes Project
Researchers at the McKusick-Nathans Institute of Genetic Medicine (IGM) at Johns Hopkins will join other national and international scientists in the 1000 Genomes Project, an ambitious effort that will involve sequencing the genomes of numerous people from around the world to create the most detailed and medically useful picture to date of human genetic variation.
More Drug Response Current Events and Drug Response News Articles
 |
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response (Cancer Drug Discovery and Development) by Federico Innocenti (Editor) The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In “Pharmacogenomics, Anticancer Drug Discovery, and Response”, edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides... |
 |
Rapid Response Urine Ecstasy (MDMA) Drug Test Strips, 500 ng/ml Cut off, 50/Bx by BTNX The Biotechnostix One-Step Drug Test is a rapid qualitative urine test for the detection of Ecstasy drug in urine. Features of the Ecstasy Drug Test: A simple to use dip-and-read test designed to detect a specific drug in urine. 99% accurate. Results ready in minutes. Cut off 500 ng/ml. FDA Cleared. Set-to SAMHSA Cut-off levels. The product referenced on this detail page is sold be 50/Bx. |
 |
Degree Women's Antiperspirant & Deodorant, Ultra Clear, Pure Clean, 2.6 oz (Pack of 4) by Degree With Triclear. Body responsive. 100% Little black dress approved. Women. Made in U.S.A. |
 |
Bravefinch Also With: Jon Pollack (Producer), Pamela Fryman (Producer), Kevin C. Slattery (Producer), Bernie Brillstein (Producer), Brad Grey (Producer), Steven Levitan (Producer) |
 |
President Bush's Speech on Drugs / Democratic Response on Drug Strategy By Senator Biden, 1989 Experience the American Journey through our country's visual heritage in this historical recording provided by the National Archives of the United States.PRESIDENT BUSH'S SPEECH ON DRUGS AND THE DEMOCRATIC RESPONSE ON DRUG STRATEGY BY SENATOR BIDEN.From the U.S. Information Agency.This historical recording from the National Archives may contain variations in audio and video quality based on the limitations of the original source material.The content summary for this DVD is adapted from an historical description provided by the government agency or donor at the time of production release. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
First Response 1 Step Ovulation Test by Church & Dwight Ovulation test kit |
 |
Rape - GHB and Rohypnol: First Response Investigation DVD by AIMS Multimedia Rape - GHB and Rohypnol: First Response Investigation explores the growing problem of date rapes and the drugs often employed by the rapist. |
 |
Milady's Aesthetician Series: Common Drugs and Side Effects: A Handbook for the Aesthetician by Pamela Hill (Author) This guide is designed to act as a quick drug reference for the aesthetician who requires information on drugs, their purpose, drug interactions, and potential effects and side effects, especially as they pertain to skin conditions. This unique resource highlights drugs that will impact the skin, and as such, the ability to treat the skin with traditional topical or clinical treatments familiar in the spa or medical spa. Designed to increase knowledge in specific categories that are beneficial to patient care, the guide is organized to include coverage of common drugs for women; drugs used in the aging process; drugs used for autoimmune diseases; drugs for bacterial infections, viral infections, and fungal infections; drugs that affect the skin; drugs used for skin therapies; illegal... |
 |
Drug Synergism and Dose-Effect Data Analysis by Ronald J. Tallarida (Author) Not since this author's bestselling Manual of Pharmacologic Calculation-long out of print-has there been a reference available for drug data analysis, and even that work did not deal with drug combinations. Although pharmacologists and most other scientists know what synergism is, mainstream textbooks tend to neglect it as a quantitative topic. Few researchers are familiar with the quantitative methodology needed to differentiate synergistic responses from the simply additive responses expected from drug combinations or a single drug's interaction with endogenous chemicals.In Drug Synergism and Dose-Effect Data Analysis, noted pharmacologist, mathematician, and author Ronald J. Tallarida finally brings these methods to light. Drawing on statistical theory and methods but keeping the... |
 |
Atypical Antipsychotics and the Spectrum Anxiety Disorders - A Video Symposium Also With: William Glazer M.D. (Primary Contributor), Mark B. Hamner M.D. (Primary Contributor), Prakash S. Masand M.D. (Primary Contributor) Current profiles indicate that U.S. clinicians prescribe a substantial amount of atypical antipsychotic medications of label, i.e. for non-schizophrenic conditions. The pharmacologic profile of the new generation medications, including clozapine, risperidone, olanzapine, quetiapine and ziprasidone, would support such use but are there studies showing clinical efficacy ni off label disease states? In particular, anxiety spectrum disorders, such as Post Traumatic Stress Disorder, Obsessive Compulsive Disorder and Attention Deficit Hyperactivity Disorder, have been shown to respond to treatment with the atypical antipsychotic agents. This PsychLink will explore this phenomenon ad present the therapeutic basis for such practice. |
| © 2009 BrightSurf.com |